What is the company's financial performance for the first quarter of 2002?

Boston Scientific reported a net income of $82 million, or $0.20 per diluted share, for the three months ended March 31, 2002. This is a significant improvement from a net loss of $5 million, or ($0.01) per diluted share, in the same period of 2001. Net sales increased by 3% to $675 million.

What are the key drivers behind the improved profitability?

The improved profitability is attributed to a modest increase in net sales, a significant improvement in gross profit margin (from 66.1% to 69.3%), and a reduction in amortization expenses due to the adoption of new accounting standards (FASB Statement No. 142). Additionally, the company recorded after-tax charges in Q1 2001 that were not present in Q1 2002.

How is the company addressing its product portfolio, especially concerning coronary stents?

The company is experiencing a decline in sales for its older NIR® coronary stents but is seeing growth in other product lines and through recently acquired businesses. Internationally, the Express® coronary stent has launched, and the company is investing heavily in its TAXUS™ drug-eluting stent technology, with a planned U.S. launch in late 2003, to capture future market share.

What are the significant risks and uncertainties facing the company?

Key risks include intense competition in the coronary stent market, the successful integration of recent acquisitions, ongoing patent litigation with major competitors, and potential delays or failures in the development and launch of new technologies like drug-eluting stents. The company is also undergoing a global operations restructuring.

BSX 10-Q Quarterly Report Q1 FY2002 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation (BSX) reported a return to profitability in the first quarter of 2002, with net income of $82 million, or $0.20 per diluted share, a significant improvement from a net loss of $5 million in the prior year's first quarter. This turnaround was driven by a 3% increase in net sales to $675 million and improved gross margins. The company is actively managing its product portfolio, with growth in segments outside of coronary stents, while addressing the decline in its older NIR® coronary stent sales. Significant investments in research and development, particularly for its drug-eluting stent technology (TAXUS program), signal a focus on future growth opportunities. Despite the positive net income, the company faces ongoing challenges including intense competition in the coronary stent market, the need to successfully integrate recent acquisitions, and a substantial number of legal proceedings, particularly patent disputes with major competitors like Johnson & Johnson. The company is also undergoing a global operations restructuring expected to be completed in Q2 2002. Management is focused on navigating these challenges and capitalizing on new technologies to drive future revenue and profitability.

Key Highlights

1Returned to profitability with net income of $82 million ($0.20/share) in Q1 2002, compared to a net loss of $5 million ($0.01/share) in Q1 2001.
2Net sales increased by 3% to $675 million, with international sales showing strong growth on a constant currency basis (11%).
3Gross profit margin improved to 69.3% from 66.1% year-over-year, partly due to cost improvements from the global operations plan.
4Research and development expenses increased to 11% of sales, reflecting significant investment in drug-eluting stent technology (TAXUS program).
5Adoption of FASB Statement No. 142 led to a reduction in amortization expense, positively impacting net income.
6The company is actively managing its product mix, with growth in areas other than coronary stents and a continued decline in NIR® coronary stent sales.
7Significant legal proceedings, primarily patent disputes, remain a key factor to monitor.

BOSTON SCIENTIFIC CORP Quarterly Report for Q1 Ended Mar 31, 2002

Summary

Key Highlights

Frequently Asked Questions